Insiders With Their Considerable Ownership Were the Key Benefactors as Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) Touches CN¥3.3b Market Cap
Insiders With Their Considerable Ownership Were the Key Benefactors as Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) Touches CN¥3.3b Market Cap
Key Insights
主要见解
- Nanjing Hicin Pharmaceutical's significant insider ownership suggests inherent interests in company's expansion
- The top 2 shareholders own 52% of the company
- Using data from company's past performance alongside ownership research, one can better assess the future performance of a company
- 南京希钦药业的重大内部人持股表明了公司扩张的内在利益
- 最大的两个股东拥有公司52%的股份
- 使用来自公司过去业绩的数据以及所有权研究,可以更好地评估公司未来的业绩
To get a sense of who is truly in control of Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584), it is important to understand the ownership structure of the business. We can see that individual insiders own the lion's share in the company with 62% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
要弄清楚谁真正控制了南京希钦药业股份有限公司(深交所:300584),了解该企业的所有权结构是很重要的。我们可以看到,个人内部人士拥有公司的最大份额,拥有62%的股份。换句话说,该集团将从他们对公司的投资中获得最大(或损失最大)。
Clearly, insiders benefitted the most after the company's market cap rose by CN¥550m last week.
显然,在该公司市值上周上涨5.5亿元后,内部人士受益最大。
Let's delve deeper into each type of owner of Nanjing Hicin Pharmaceutical, beginning with the chart below.
让我们从下面的图表开始,更深入地调查南京希信药业的每一种类型的所有者。
See our latest analysis for Nanjing Hicin Pharmaceutical
查看我们对南京希钦药业的最新分析
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231013/0-bbe63fdf7836b4cc994451bedd73cbc5-0-9baadb42c1dbff85b5d2bf13c1235eb8.png/big)
What Does The Institutional Ownership Tell Us About Nanjing Hicin Pharmaceutical?
关于南京希钦药业,机构持股告诉了我们什么?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构以一个接近当地市场的指数来衡量它们的表现。因此,他们通常更关注那些被纳入主要指数的公司。
Less than 5% of Nanjing Hicin Pharmaceutical is held by institutional investors. This suggests that some funds have the company in their sights, but many have not yet bought shares in it. So if the company itself can improve over time, we may well see more institutional buyers in the future. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too.
机构投资者持有南京希信药业不到5%的股份。这表明,一些基金瞄准了该公司,但许多基金尚未购买该公司的股票。因此,如果公司本身能够随着时间的推移而改善,我们很可能会在未来看到更多的机构买家。当几家大机构想要同时购买某只股票时,我们有时会看到股价上涨。下面你可以看到的收益和收入的历史,可能有助于考虑是否有更多的机构投资者会想要这只股票。当然,还有很多其他因素需要考虑。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231013/0-bbe63fdf7836b4cc994451bedd73cbc5-1-0c8762920189c7d1f0b39d93e10a114b.png/big)
We note that hedge funds don't have a meaningful investment in Nanjing Hicin Pharmaceutical. Looking at our data, we can see that the largest shareholder is Yu Ping Cao with 42% of shares outstanding. With 10.0% and 6.7% of the shares outstanding respectively, Xiao Qun Jiang and Xiao Quan Liu are the second and third largest shareholders.
我们注意到,对冲基金没有对南京希信药业进行有意义的投资。看看我们的数据,我们可以看到,第一大股东是喻屏曹操,持有42%的流通股。蒋小群和刘小泉分别持有10.0%和6.7%的流通股,是第二大股东和第三大股东。
After doing some more digging, we found that the top 2 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
在进一步挖掘后,我们发现,前两名股东共同控制着公司一半以上的股份,这意味着他们拥有相当大的权力来影响公司的决策。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.
虽然研究一家公司的机构持股可以增加你的研究价值,但研究分析师的建议以更深入地了解一只股票的预期表现也是一个很好的做法。目前,我们没有注意到分析师对该股的报道,因此该公司不太可能被广泛持有。
Insider Ownership Of Nanjing Hicin Pharmaceutical
南京希钦药业的内部人所有权
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
公司内部人的定义可能是主观的,而且在不同的司法管辖区之间确实有所不同。我们的数据反映了个别内部人士,至少捕捉到了董事会成员。公司管理层对董事会负责,董事会应代表股东的利益。值得注意的是,有时最高层管理人员本身也是董事会成员。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多数人认为内部人持股是积极的,因为它可以表明董事会与其他股东很好地结盟。然而,在某些情况下,太多的权力集中在这个群体中。
It seems that insiders own more than half the Nanjing Hicin Pharmaceutical Co., Ltd. stock. This gives them a lot of power. Given it has a market cap of CN¥3.3b, that means they have CN¥2.1b worth of shares. Most would be pleased to see the board is investing alongside them. You may wish todiscover (for free) if they have been buying or selling.
看来,内部人士持有南京希钦药业股份有限公司一半以上的股份。这给了他们很大的权力。鉴于它的市值为人民币33亿元,这意味着他们拥有价值人民币21亿元的股票。大多数人会高兴地看到董事会与他们一起投资。您可能希望发现(免费)如果他们一直在买入或卖出。
General Public Ownership
一般公有制
The general public, who are usually individual investors, hold a 34% stake in Nanjing Hicin Pharmaceutical. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
公众通常是个人投资者,他们持有南京希钦药业34%的股份。这种规模的所有权虽然可观,但如果决策与其他大股东不同步,可能不足以改变公司政策。
Next Steps:
接下来的步骤:
It's always worth thinking about the different groups who own shares in a company. But to understand Nanjing Hicin Pharmaceutical better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Nanjing Hicin Pharmaceutical (at least 1 which is a bit concerning) , and understanding them should be part of your investment process.
拥有一家公司股票的不同集团总是值得考虑的。但要更好地了解南京希钦药业,还需要考虑许多其他因素。例如,考虑一下无处不在的投资风险幽灵。我们已经确定了三个警告信号与南京希信药业合作(至少1家,这有点令人担忧),了解他们应该是你投资过程的一部分。
Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.
当然了这可能不是最值得购买的股票。。所以让我们来看看这个免费 免费有趣的公司名单。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。